Diabetes. E11
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients with mild to moderate type 2 diabetes Age 40 to 60 years Have diabetes for at least two years Under treatment with or without anti-diabetic drugs Fasting blood glucose levels between 130 to 170 mg/dL Glycosylated hemoglobin between 7.5 to 8.5%
Exclusion criteria
Exclusion criteria: Patients with diabetic foot ulcer and gangrene Patients with any severe illness Patients with painful diabetic neuropathy Depressed patients Smokers or alcoholic patients Patients who tend to change their exercise program or diet
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glycosylated hemoglobin. Timepoint: At starting of the study and after 3 months. Method of measurement: Glycosylated hemoglobin will be determined in laboratory by commercial standard kit.;Fasting blood glucose. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood glucose level will be determined in laboratory by commercial standard kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Triglyceride. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood triglyceride level will be determined in laboratory by commercially available kit.;Cholesterol. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood cholesterol level will be determined in laboratory by commercially available kit.;Low-density lipoprotein. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood low-density lipoprotein level will be determined in laboratory by commercially available kit.;High-density lipoprotein. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood High-density lipoprotein level will be determined in laboratory by commercially available kit.;Aspartate aminotransferase. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood aspartate aminotransferase level will be determined in laboratory by commercially available kit.;Alanine aminotransferase. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood alanine aminotransferase level will be determined in laboratory by commercially available kit.;Blood urea nitrogen. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood blood urea nitrogen level will be determined in laboratory by commercially available kit.;Creatinine. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood creatinine level will be determined in laboratory by commercially available kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Iranian academic center for education culture and research